MOUNTAIN VIEW, Calif., Jan. 4, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. today announced that the company will present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011 at 8:00 a.m. PT in San Francisco.
A live webcast of the presentation will be available on the Investor Relations section of MAP Pharmaceuticals' website at http://www.mappharma.com/. A replay will also be available within 24 hours for seven days following the presentation.
About MAP Pharmaceuticals
MAP Pharmaceuticals is an emerging biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX(TM) orally inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of its Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.
Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com/.
CONTACT: Alex Bowie WCG (212) 301-7201 abowie@wcgworld.com
MAP Pharmaceuticals, Inc.
CONTACT: Alex Bowie of WCG, +1-212-301-7201, abowie@wcgworld.com, for
MAP Pharmaceuticals, Inc.
Web Site: http://www.mappharma.com/
